Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Saved in:
Bibliographic Details
Title: Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Authors: Sato Y; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Kodama T; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan t-kodama@gh.med.osaka-u.ac.jp., Maesaka K; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Kai M; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Murai K; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Tahata Y; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Saito Y; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Nakabori T; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan., Ohkawa K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan., Tanaka S; Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Sakamori R; Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Miyazaki M; Department of Gastroenterology and Hepatology, Osaka Police Hospital, Osaka, Japan., Furuta K; Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Japan., Ishida H; Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Japan., Matsumoto K; Department of Gastroenterology and Hepatology, Toyonaka Municipal Hospital, Toyonaka, Japan., Tawara S; Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan., Yakushijin T; Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan., Nozaki Y; Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan., Hosui A; Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai, Japan., Nishio A; Department of Gastroenterology and Hepatology, Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan., Tatsumi N; Department of Gastroenterology and Hepatology, Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan., Kakita N; Department of Gastroenterology and Hepatology, Kaizuka City Hospital, Kaizuka, Japan., Yoo C; Department of Oncology, University of Ulsan College of Medicine, Songpa-gu, Korea (the Republic of)., Fukai M; Department of Gastroenterological Surgery I, Hokkaido University, Sapporo, Japan., Taketomi A; Department of Gastroenterological Surgery I, Hokkaido University, Sapporo, Japan., Hikita H; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Tatsumi T; Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan., Takehara T; Kansai Rosai Hospital, Amagasaki, Japan.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Apr 09; Vol. 14 (4). Date of Electronic Publication: 2026 Apr 09.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2025-013384